Author(s)

Emilija Sagaityte^1*, Richard S. Dowd², Kendall Lane², Stephanie L. Graff³, Steven A. Toms²

¹Department of Neurosurgery, Warren Alpert School of Medicine, Brown University, Providence, USA.
²Department of Neurosurgery, Rhode Island Hospital, Lifespan Health System, Providence, USA.
³Lifespan Cancer Institute, Rhode Island Hospital, Legorreta Cancer Center at Brown University, Providence, USA.

Breast cancer is one of the most commonly diagnosed cancers and one of the most significant sources of cancer mortality. Triple negative breast cancer (TNBC) is a particularly aggressive subtype that has proven difficult to treat with standard chemotherapies. Obesity has also been shown to exacerbate breast cancer, and diagnoses of these two diseases frequently overlap. Both conditions are regulated in part by the fat mass and obesity-associated (FTO) demethylase, an RNA demethylase which may drive breast cancers through epigenetic alterations to gene expression. Methods of inhibiting FTO have been researched in vitro and in vivo as an alternative or adjunct to chemotherapies in multiple cancers, including breast cancer. Translating knowledge of the role of FTO in breast cancer and the development of novel agents may allow for improvements in the treatment of this refractory cancer. This review therefore aims to provide an overview of existing and developing chemical inhibitors of FTO that could be innovatively studied for the treatment of TNBC and associated comorbidity.

Breast Cancer, Obesity, Fat Mass and Obesity-Associated, Chemotherapy, Ep-igenetics, RNA

Sagaityte, E. , Dowd, R. , Lane, K. , Graff, S. and Toms, S. (2023) The Role of RNA Epitranscriptomics and the RNA Fat Mass and Obesity-Associated Demethylase in Triple Negative Breast Cancer. Advances in Breast Cancer Research, 12, 27-50. doi: 10.4236/abcr.2023.122004.